The first experimental heart transplantation was performed
|
|
- Mervin Day
- 5 years ago
- Views:
Transcription
1 Myocardial Preservation Using Celsior Solution in Cardiac Transplantation: Early Results and 5-Year Follow-Up of a Multicenter Prospective Study of 70 Cardiac Transplantations Jean-Paul Remadi, MD, Olivier Baron, MD, Jean C. Roussel, MD, Oussana Al Habash, MD, Michele Treilhaud, MD, Philippe Despins, MD, Daniel Duveau, MD, and Jean-Luc Michaud, MD Cardiovascular Surgery Unit and Department of Anesthesiology, The G and R Laënnec University Hospital, Nantes, France Background. Several storage methods using a wide variety of extracellular or intracellular solutions applied either as continuous perfusion, intermittent perfusion, or simple immersion of the heart have been commonly used. We have performed a prospective randomized multicenter study of 70 cardiac transplantation recipients to evaluate the Celsior solution for cardiac preservation. Methods. Seventy consecutive patients were included in this trial and received a cardiac graft arrested and preserved with Celsior. The first follow-up period was 1 month. The mean age of the recipients was 49 years (range, 28 to 66 years), and 81.7% were male. The main disease was nonobstructive cardiomyopathy (64.3%). The age range of donors was between 14 and 56 years with a mean of 33 years. The majority of grafts (73%) were stored in 1 L of Celsior. A midterm follow-up at 5 years was performed and was 100% complete. Results. The operative mortality (<30-day) rate was 6 of 70 (8.6%). Sixty-three patients (90%) had at least satisfactory hemodynamic measurements on day 2. The first postoperative echocardiograms showed good myocardial performance for 90% of the grafts. Actuarial survival rate at 5 years was 75% 5.1%. Conclusions. The use of Celsior in cardiac transplantation was safe and very effective. This solution proved very valuable in at-risk patients. (Ann Thorac Surg 2002;73:1495 9) 2002 by The Society of Thoracic Surgeons The first experimental heart transplantation was performed by Carrel and Guthrie in 1905 [1] and afterwards by Mann and associates in 1933 [2], who transplanted dog hearts heterotopically. In 1959, Lower and colleagues [3] at Stanford University succeeded in transplanting a dog heart in the orthotopic position. In 1993 there were 4,789 heart and 191 heart-lung transplantations performed in Europe and the United States [4]. Myocardial protection in a cardiac transplantation procedure consists of four steps: inducing cardiac arrest, preservation of the transplant, global ischemia associated with the implantation of the graft, and reperfusion. One of the principal reasons for failure of the procedure as a whole is malfunctioning of the graft owing to improper preservation during the explantation, storage, and transport period, which becomes apparent after restoration of blood flow. Thus far, storage intervals of 4 to 5 hours represent the safe maximum in clinical heart preservation [5, 6]. Several storage methods using a wide variety of extracellular or intracellular solutions applied either as continuous perfusion, intermittent perfusion, or simple Accepted for publication Jan 11, Address reprint requests to Dr Remadi, Cardiovascular Surgery Unit, South Hospital, Amiens Cedex 1, Nantes, France; remadijean-paul@chu-amiens.fr. immersion of the heart have been commonly used. Celsior is an organ preservation solution designed for myocardium, especially for transplantation procedures [7]. Several preclinical trials and two clinical studies were performed with Celsior [8 12]. In these trials, Celsior has proven to be as safe as and slightly more effective than the currently approved myocardial preservation solutions for cardiac transplantation. Celsior is an organ preservation solution designed for myocardial protection. Its chemical composition accounts for the basic principles of organ preservation in general and that of the myocardium specifically. Celsior also takes into account the specific requirements of graft during the four different stages of transplantation: initial cardioplegia of the donor s heart, conservation, ischemia, and reperfusion. Celsior is an extracellular solution. The reduction of the oxidative lesions is caused by mannitol, histidine, and reduced glutathione, which are the essential components of the solution. Celsior also has been designed to counteract the two major mechanisms causing calcium overload: ischemia-induced loss of high-energy phosphates and entry of calcium from the extracellular space. This is achieved by using an appropriate balanced solution of low calcium that is slightly hyperkalemic and contains high concentrations of sodium and magnesium; this 2002 by The Society of Thoracic Surgeons /02/$22.00 Published by Elsevier Science Inc PII S (02)
2 1496 REMADI ET AL Ann Thorac Surg MYOCARDIAL PRESERVATION USING CELSIOR SOLUTION 2002;73: Table 1. Baseline Recipient Data Characteristic Range Mean Age (years) Retransplantation 0 0 Body surface PAP (mm Hg) PAR (Wood units) n % Sex Female Male Pathology Nonobstructive cardiomyopathy Ischemic cardiomyopathy Valvular cardiomyopathy PAP pulmonary artery pressure; resistance. permits energy production in anaerobic situations, thus limiting the ATP-dependent process of calcium contracture of the myocardium. The primary objective of this prospective and multicenter study was to confirm the positive results obtained from previous clinicals trials and to increase the amount of available safety data for Celsior. Patients and Methods PAR pulmonary arterial This study was multicenter (six French cardiac centers) and prospective. Seventy consecutive patients were included in this trial and received a cardiac graft arrested and preserved with Celsior. The follow-up periods were 1 month and 5 years. All patients reporting to each center were asked to participate if they fit within inclusion and exclusion criteria (Table 1). Patients who signed informed consent were subsequently included into the trial. The first patient was included in July 1995, and the last patient in November The mean age of the recipients was 49 years (range, 28 to 66 years), and 81.7% were male. The main disease was nonobstructive cardiomyopathy (64.3%). The majority of recipients had an elevated pulmonary artery resistance (PAR; Table 2). Patients with PAR more than 4 wood units have to be considered at risk for posttransplant complications such as right ventricular failure, especially when other risk factors, such as long ischemia time, are added. The efficacy of Celsior was therefore analyzed separately in cases of extremely increased PAR ( 5 Wood units). Five patients were using mechanical assist devices before transplantation. These included three total artificial hearts (Jarvick) and two left ventricular assist devices (one Novacor, one Thoratec). The age range of the donors was between 14 and 56 years, with a mean of 33 years. Four donors were older than 50 years, and their hearts were thus regarded as at-risk organs. All hearts derived from female donors (22.8%) were also classed as at-risk grafts. The average duration of anesthesia was 17 hours, ranging from 6 to 48 hours. Fifty-one donors required less than 5 mg kg 1 min 1 of dopamine or dobutamine support, and these patients were classed as stable. Consequently, 27.2% of the donors presented with an unstable circulation requiring epinephrine support or dopamine or dobutamine at doses more than 5 mg kg 1 min 1 at the time of harvesting. Forty percent of the donor hearts were arrested using 2LofCelsior solution; the remainder hearts were arrested using only 1 L. The majority of grafts (73%) were stored in 1 L of Celsior solution. The others were stored in either more (17%) or less (10%). The mean use of Celsior was approximately 3 L per procedure. Celsior solution was not used during the transplantation procedure, and the implantation was performed according to the usual protocol at the center. Thus, 64.3% of the procedures were performed with local and moderate systemic hypothermia, 13 patients received coldblood cardioplegic solution combined with blood reperfusion, and one patient received warm-blood reperfusion only. Measures of the quality of myocardial preservation for this trial were hemodynamic and clinical measurements, enzyme release, histologic assessment of biopsy samples, and assessment of adverse events. According to the data obtained the graft was classified as one of the following: hemodynamically satisfactory graft function; right ventricular insufficiency with or without pulmonary hypertension; and global cardiac insufficiency. All drugs prescribed for supporting the hemodynamic status of the graft were documented throughout the first week of the trial. To facilitate comparison with other authors and trials, an inotropic scoring system (Vlessis score), taking into account the medication within the first 24 hours, was produced. Univariate and multivariate analyses (logistic regressions) were performed to determine which preoperative factors were related to early and late mortality (Statistical logical Statview). A midterm follow-up was performed at 5 years with a cumulative total of 3,929 months and a mean of 51 months. Results Mean graft ischemia time was 186 minutes (Table 3). Reperfusion was defined as the time between removal of the aortic clamp and weaning from cardiopulmonary bypass; it was close to 30 minutes (Table 3). Fifty percent of the grafts defibrillated spontaneously; Table 2. Distribution of Patients According to Pulmonary Artery Resistance PAR (Wood units) n % PAR pulmonary arterial resistance.
3 Ann Thorac Surg REMADI ET AL 2002;73: MYOCARDIAL PRESERVATION USING CELSIOR SOLUTION 1497 Table 3. Implantation Data Variable Range Mean CPB time (min) Duration of storage (min) Reperfusion time (min) Total ischemia time (min) CPB cardiopulmonary bypass. the remainder required between one and two electrical shocks before converting to sinus rhythm. Only 1 patient required the insertion of an atrioventricular pacemaker. The mean hemodynamic data at 0, 24, and 48 hours are listed in Table 4. Mean blood pressure was approximately 80 mm Hg, mean pulmonary wedge pressure was approximately 11 mm Hg, and mean cardiac output was approximately 6 L/minute. The subjective opinion of the investigators appears to match the hemodynamic data closely. Sixty-three patients (90%) had at least satisfactory hemodynamic conditions on day 2. Seven patients experienced initial hemodynamic problems related to graft failure: 5 experienced right heart failure and 2 experienced global cardiac insufficiency. Four patients required postoperative insertion of a circulatory support device. Operative mortality ( 30-day) rate was 6 of 70 (8.6%). Main postoperative noncardiac complications are listed in Table 5. Seventeen patients (24.3%) experienced an infection, 5 patients (5.1%) experienced neurologic events, and 7 patients (10%) experienced renal failure. All cardioactive medications were recorded throughout the first week of the trial: the inotropic score amounted to 171 (Table 6). Cardiac enzymes were at normal levels at 0, 24, and 48 hours after transplantation (Table 7). Enzyme levels of cardiac creatine kinase were lower than 10%. This fact shows that Celsior solution achieves effective protection of the graft. The first postoperative echocardiograms showed good myocardial performance for 90% of the grafts (mean shortening fraction, 35%). The remaining 10% of patients experienced cardiac failure as outlined. Univariate analysis showed that age more than 60 years (p 0;02), PAR (p 0.001), and an ischemic time less than 4 hours (p 0.01) were related to a higher mortality rate. The multivariate regression analysis showed only the PAR (p 0.001) to be an independent factor related to early mortality. Table 5. Postoperative Complications Complication n % Renal failure 7 10 Infections Bacteriemia CMV Pneumonia Sternal Neurologic 5 7 Convulsions CVA Cubital compression CMV cytomegalovirus; CVA cerebrovascular accident. Early Results According to Risk Groups Clearly, when there is already some damage (long ischemia, older donor), less myocardial tissue (female donor), or a requirement for excellent immediate function (pulmonary artery hypertension, older recipient), it is of paramount importance to avoid preservation damage, and it may be then Celsior is at its most beneficial. Preoperative Pulmonary Hypertension Eight patients had preoperative PAR more than 5 Wood units. All of these patients required some form of cardiac drug support postoperatively coming off bypass or during the first 48 hours. A well-preserved graft in conjunction with vasodilators such as nitric oxide was beneficial for these recipients to overcome the difficult first days after the procedure. The mortality rate was 25%. Infection was the cause of the two deaths (pulmonary infection and septicemia after colic perforation) after prolonged intensive care stay caused by a primary graft failure (PAR, 5.6 and 8.8 Wood units preoperatively for the recipients). Ischemia Time More Than 4 Hours Ten patients received grafts with an ischemia time of more than 4 hours (14.3%). One patient died of right ventricular failure, 1 patient required temporarily a right ventricular assist device but recovered without problems, and 2 patients required inotropic agent support on coming off cardiopulmonary bypass or in the postoperative period but recovered without further problems. The outcome was thus favorable in 9 of 10 patients with prolonged ischemia time. Table 4. Early Hemodynamic Data Variable 0 hours 24 hours 48 hours Mean systemic arterial pressure (mm Hg) Mean right atrial pressure (mm Hg) Mean pulmonary artery pressure (mm Hg) Mean pulmonary wedge pressure (mm Hg) Cardiac frequency (beats/min) Cardiac output (L/mn)
4 1498 REMADI ET AL Ann Thorac Surg MYOCARDIAL PRESERVATION USING CELSIOR SOLUTION 2002;73: Table 6. Inotropic Score (Vlessis) Inotropic Agent Score Epinaphrine 56 Dobutamine 13 Dopamine 37 Isoprenaline 65 Total 171 Donor Age More Than 50 Years Five patients received hearts from donors older than 50 years. There was one death in this group with a long ischemia time added (270 minutes). One patient required a right ventricular support device (Biomedicus centrifugal pump) and recovered fully without further complications. Recipient Age More Than 50 Years Thirty recipients were older than 50 years (42.8%), and 11 patients were older than 60 years (15.7%). Four (13.3%) of the 30 patients more than 50 years of age died; thus the mortality rate was comparable to the overall mortality. Two (18.1%) of the 11 patients in the age group more than 60 years died. This mortality is higher than the global mortality (not significant). Female Donor Sixteen recipients received heart grafts from female donors. Among these recipients, 6 were women and 10 men. One patient died (6.3%), and 1 patient required circulatory assistance. Midterm Results The follow-up was 100% complete at 5 years. Sixteen deaths (including operative mortality) occurred. The actuarial survival rate at 5 years was 75% 5.1% (Fig 1). The main cause of the 10 late deaths was neoplasm (40%). There was only one terminal cardiac failure responsible for one late death (6.25%). We obtained echocardiogram data for 32 patients who were alive (59.25%): the mean shortening fraction was 31% 3.1%. A multivariate analysis showed none of the factors were significantly related to the late mortality. Comment The deleterious effects of myocardial ischemia have been extensively demonstrated [13], and there is convincing evidence that oxygen-derived free radicals are important Table 7. Postoperative Myocardial Enzyme Levels Enzyme 0 hours 24 hours 48 hours CK CKMB LDH CK creatine kinase; CKMB cardiac creatine kinase; LDH lactate dehyrogenase. Fig 1. Actuarial survival curve. mediators of myocardial damage resulting from ischemia [14, 15]. Additionally, calcium overload has been shown to be a key determinant in myocardial stiffness. Celsior achieves superior results when compared with standard preservation fluids by reducing myocardial edema [7], reducing free oxygen radical production [8 14], and limiting calcium overload [7]. The use of Celsior in this trial setting was associated with a low 30-day mortality rate of 8.6%. These results compare favorably with the international standards set for heart transplantation (Clinical transplant 1994, ISHLT registry 1996). Atrial fibrillation and heart block rates were very low (only one posttransplantation pacemaker was necessary). We also used Celsior solution for cardioplegia in a standard cardiac procedure (coronary artery bypass grafting with valve replacement). In this trial, 300 patients were operated on during a period of 3 months: 150 were perfused with Bretschneider solution and 150 with Celsior. This trial showed that atrial fibrillation and heart block rates were significantly lower with Celsior, as we observed with cardiac transplantation. These results confirm that Celsior is very effective for preserving cardiac sinus rhythm. The low cardiac output syndrome rate was also low, and inotropic support was not frequent ( 10%). Taking into consideration that Celsior achieved the same results when the patient population was stratified according to different risk groups, one can state that this study had an excellent clinical outcome. Indeed, the morbidity and mortality for at-risk patients did not significantly differ from standard cardiac recipients. For the severe pulmonary hypertension group (PAR 5 Wood units), operative mortality was significantly higher. The center at Stanford University published similar results with an operative mortality of 7.9% and an increased mortality risk for the pulmonary hypertension subgroup and for women. Other clinical trials with Celsior solution to preserve donor hearts have shown similar good early results [16, 17]. The late results show a high survival rate (75% 5.1%), comparable to published data (ISHLT registry 1996), and confirm the good early results. The use of Celsior in cardiac transplantation was safe and very effective. This solution to be very valuable in at-risk patients. Further clinical work can and should be performed using it. The midterm evaluation of this group of patients shows an excellent survival rate at 5 years and leads us to use Celsior for cardiac preservation.
5 Ann Thorac Surg REMADI ET AL 2002;73: MYOCARDIAL PRESERVATION USING CELSIOR SOLUTION 1499 The authors acknowledge five cardiac centers: Lyon (Prof Champsaur and Prof Ninet), Lille (Prof Warembourg and Prof Prat), Strasbourg (Prof Eisenmann), Foch (Prof Guilmet and Prof Dreyfus), and Nancy (Prof Villemot). References 1. Carrel A, Guthrie CC. The transplantation of veins and organs. Am J Med 1905;10: Mann RD, Priestly IR, Markowits I. Transplantation of the intact mammalian heart. Arch Surg 1933;26: Lower RR, Stofer RC, Shumway NE. Homovital transplantation of the heart. J Thorac Cardiovasc Surg 1961;41: Hardy ID, Chavez CM, Kurru FD, et al. Heart transplantation in man. Developmental studies and report of a case. JAMA 1964;188: Transplant Council of Europe, Report. Volume 6, July 1994, Fondation Marcel Merieux, Fabiani IN, Ponzio V, Iebhera V. La protection myocardique. Techniques chirurgicales. In: Encycl Méd Chir (Paris, France) 1989, Thorax, Menasché P, Pradier F, Grousset C, et al. Improved recovery of heart transplants with a specific kit of preservation solutions. J Thorac Cardiovasc Surg 1993;105: Menasché P, Pradier F, Peynet J, et al. Limitation of free radical injury by reduced glutathione: an effective means of improving the recovery of heart transplants. Transplant Proc 1991;23: Menasché P, Termignon JL, Pietri S. Experimental evaluation of a new heart preservation solution (CELSIOR). European Society for Organ Transplantation, 6th Congress, Rhodes, October Menasché P, Termignon J-L, Pradier F, et al. Experimental evaluation of Celsior, a new heart preservation solution. Eur J Thorac Cardiovasc Surg 1994;8: Zaiac M. Comparison of the antiradical and cardioprotective effects of Celsior vs. Ringer lactate as preservation fluids for human cardiac transplantation. LPO-01 report. PMsv data on file. 12. Zaiac M, Marie V, Menasche P. Myocardial preservation using Celsior: evaluation of efficacy and safety compared to standard preservation fluids. LPO-02 study report, PMsv data on file. 13. Singh A, Lee KJ, Lee CY, Golfarb RD, Tsan MF. Relation between myocardial glutathione content and extent of ischemia-reperfusion injury. Circulation 1989;80: Menasché P, Grousset C, Gauduel Y, Piwnica A. A comparative study of free radical scavengers in cardioplegic solutions. J Thorac Cardiovasc Surg 1986;92: Astier A, Paul M. Instability of reduced glutathione in commercial Belzer cold storage solution. Lancet 1989;2: Bourdillion PDV, Poole Wilson PA. Effects of ischemia and reperfusion on calcium exchange and mechanical function in isolated rabbit myocardium. Cardiovasc Res 1981;15: Sarris EG, Moore K, Shroder J. Cardiac transplantation: the Stanford experience in the cyclosporine era. J Thorac Cardiovasc Surg 1994;108:
MODERATOR Felix Rapaport, other members of this
The First Lung Transplant in Man (1963) and the First Heart Transplant in Man (1964) J.D. Hardy MODERATOR Felix Rapaport, other members of this distinguished panel, and members of the audience, I will
More informationChairman and O. Wayne Isom Professor Department of Cardiothoracic Surgery Weill Cornell Medicine
Leonard N. Girardi, M.D. Chairman and O. Wayne Isom Professor Department of Cardiothoracic Surgery Weill Cornell Medicine New York, New York Houston Aortic Symposium Houston, Texas February 23, 2017 weill.cornell.edu
More informationEACTS Adult Cardiac Database
EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationHeart transplantation is the gold standard treatment for
Organ Care System for Heart Procurement and Strategies to Reduce Primary Graft Failure After Heart Transplant Masaki Tsukashita, MD, PhD, and Yoshifumi Naka, MD, PhD Primary graft failure is a rare, but
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, radiofrequency, anesthetic considerations for, 479 489 Acute aortic syndrome, thoracic endovascular repair of, 457 462 aortic
More informationUniversity of Bristol - Explore Bristol Research
Rogers, C., Capoun, R., Scott, L., Taylor, J., Angelini, G., Narayan, P.,... Ascione, R. (2017). Shortening cardioplegic arrest time in patients undergoing combined coronary and valve surgery: results
More informationIncreasing Organ availability: From Machine Perfusion to Donors after Cardiac Death. Ayyaz Ali
Increasing Organ availability: From Machine Perfusion to Donors after Cardiac Death Ayyaz Ali No relevant financial disclosures 2 Heart Transplantation - Activity 3 Donor Heart Preservation Static preservation
More informationCardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac
More informationCardiothoracic Fellow Expectations Division of Cardiac Anesthesia, Beth Israel Deaconess Medical Center
The fellowship in Cardiothoracic Anesthesia at the Beth Israel Deaconess Medical Center is intended to provide the foundation for a career as either an academic cardiothoracic anesthesiologist or clinical
More informationUniversity of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives
University of Florida Department of Surgery CardioThoracic Surgery VA Learning Objectives This service performs coronary revascularization, valve replacement and lung cancer resections. There are 2 faculty
More informationPolicy Specific Section: May 16, 1984 April 9, 2014
Medical Policy Heart Transplant Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Transplant Original Policy Date: Effective Date: May 16, 1984 April 9, 2014 Definitions
More informationTHE HEART THE CIRCULATORY SYSTEM
THE HEART THE CIRCULATORY SYSTEM There are three primary closed cycles: 1) Cardiac circulation pathway of blood within the heart 2) Pulmonary circulation blood from the heart to lungs and back 3) Systemic
More informationAnalysis of Mortality Within the First Six Months After Coronary Reoperation
Analysis of Mortality Within the First Six Months After Coronary Reoperation Frans M. van Eck, MD, Luc Noyez, MD, PhD, Freek W. A. Verheugt, MD, PhD, and Rene M. H. J. Brouwer, MD, PhD Departments of Thoracic
More informationOPCAB IS NOT BETTER THAN CONVENTIONAL CABG
OPCAB IS NOT BETTER THAN CONVENTIONAL CABG Harold L. Lazar, M.D. Harold L. Lazar, M.D. Professor of Cardiothoracic Surgery Boston Medical Center and the Boston University School of Medicine Boston, MA
More informationHeart-lung transplantation: adult indications and outcomes
Brief Report Heart-lung transplantation: adult indications and outcomes Yoshiya Toyoda, Yasuhiro Toyoda 2 Temple University, USA; 2 University of Pittsburgh, USA Correspondence to: Yoshiya Toyoda, MD,
More informationPerioperative Management of TAPVC
Perioperative Management of TAPVC Professor Andrew Wolf Rush University Medical Center,Chicago USA Bristol Royal Children s Hospital UK I have no financial disclosures relevant to this presentation TAPVC
More informationSolution for cardiac perfusion in viaflex plastic container
CARDIOPLEGIA SOLUTION A Solution for cardiac perfusion in viaflex plastic container DESCRIPTION Cardioplegia Solution A is a sterile, non-pyrogenic solution in a Viaflex bag. It is used to induce cardiac
More informationIntra-operative Effects of Cardiac Surgery Influence on Post-operative care. Richard A Perryman
Intra-operative Effects of Cardiac Surgery Influence on Post-operative care Richard A Perryman Intra-operative Effects of Cardiac Surgery Cardiopulmonary Bypass Hypothermia Cannulation events Myocardial
More informationWHY ADMINISTER CARDIOTONIC AGENTS?
Cardiac Pharmacology: Ideas For Advancing Your Clinical Practice The image cannot be displayed. Your computer may not have enough memory to open the image, or Roberta L. Hines, M.D. Nicholas M. Greene
More informationDo we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine
Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict
More informationJournal of the American College of Cardiology Vol. 33, No. 6, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 33, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00061-3 for Prediction
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationIntra-operative Echocardiography: When to Go Back on Pump
Intra-operative Echocardiography: When to Go Back on Pump GREGORIO G. ROGELIO, MD., F.P.C.C. OUTLINE A. Indications for Intraoperative Echocardiography B. Role of Intraoperative Echocardiography C. Criteria
More informationHeart Transplantation in Seniors European View
Heart Transplantation in Seniors European View Hynek RIHA Department of Anesthesiology and Intensive Care Institute for Clinical and Experimental Medicine Prague, Czech Republic 3 rd Int l Symposium: Perioperative
More informationManaging Hypertension in the Perioperative Arena
Managing Hypertension in the Perioperative Arena Optimizing Perioperative Management Strategies for Hypertension in the Cardiac Surgical Patient Objectives: Treatment of hypertensive emergencies. ALBERT
More informationOff-Pump Cardiac Surgery is not Dead
Off-Pump Cardiac Surgery is not Dead Gonzalo J. Carrizo, M.D. Fellow Cardiothoracic Surgery Division Cardiothoracic Surgery Department of Surgery University of Colorado Hopeman Lectureship September 10,2007
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationRhythm Disorders 2017 TazKai LLC and NRSNG.com
Rhythm Disorders 1. Outline the conduction system of the heart. 2. What do the different portions of the EKG represent? 3. Define the following terms: a. Automaticity b. Conductivity c. Excitability d.
More informationPreconditioning is defined as the cardioprotective effects
Preconditioning Prevents Myocardial Stunning After Cardiac Transplantation Roderick W. Landymore, MD, Alexander J. Bayes, MD, J. Thomas Murphy, MD, and John H. Fris, RT King Fahad National Guard Hospital,
More informationPostoperative atrial fibrillation is not an innocuous arrhytmia in LAVD patients
Accepted Manuscript Postoperative atrial fibrillation is not an innocuous arrhytmia in LAVD patients Cipriano Abad, MD, PhD, FEBS(Hon, Gen Surg), EBCTS, Stefano Urso, MD, PhD, Bernardino Clavo, MD, PhD
More informationDifficult Scenarios for Myocardial Protection SAHA Gil Bolotin M.D., Ph.D. Rambam Medical Center, Haifa, Israel
Difficult Scenarios for Myocardial Protection SAHA 2017 Gil Bolotin M.D., Ph.D. Rambam Medical Center, Haifa, Israel Difficult Scenarios for Myocardial Protection Stone Heart Nightmare Nightmare of the
More informationIndex. Note: Page numbers of article titles are in boldface type. Heart Transplantation
Heart Transplantation Index Note: Page numbers of article titles are in boldface type. Accelerated graft atherosclerosis (AGA), post heart transplantation, 73-74 Acute rejection, of heart, in adults, 70
More informationCARDIOVASCULAR SURGERY
Volume 107, Number 4 April 1994 The Journal of THORACIC AND CARDIOVASCULAR SURGERY Cardiac and Pulmonary Transplantation Risk factors for graft failure associated with pulmonary hypertension after pediatric
More informationCardiac anaesthesia. Simon May
Cardiac anaesthesia Simon May Contents Cardiac: Principles of peri-operative management for cardiac surgery Cardiopulmonary bypass, cardioplegia and off pump cardiac surgery Cardiac disease and its implications
More informationLactate Release During Reperfusion Predicts Low Cardiac Output Syndrome After Coronary Bypass Surgery
Lactate Release During Reperfusion Predicts Low Cardiac Output Syndrome After Coronary Bypass Surgery Vivek Rao, MD, PhD, Joan Ivanov, RN, MSc, Richard D. Weisel, MD, Gideon Cohen, MD, Michael A. Borger,
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationPost Cardiac Arrest Care 2015 American Heart Association Guideline Update for CPR and Emergency Cardiovascular Care
Post Cardiac Arrest Care 2015 American Heart Association Guideline Update for CPR and Emergency Cardiovascular Care รศ.ดร.พญ.ต นหยง พ พานเมฆาภรณ ภาคว ชาว ส ญญ ว ทยา คณะแพทยศาสตร มหาว ทยาล ยเช ยงใหม System
More informationRemodeling of the Remnant Aorta after Acute Type A Aortic Dissection Surgery
Remodeling of the Remnant Aorta after Acute Type A Aortic Dissection Surgery Are Young Patients More Likely to Develop Adverse Aortic Remodeling of the Remnant Aorta Over Time? Suk Jung Choo¹, Jihoon Kim¹,
More informationA Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH Frazier MD, HR Mallidi MD Division of Transplant & Assist
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationCoronary Artery Bypass Graft: Monitoring Patients and Detecting Complications
Coronary Artery Bypass Graft: Monitoring Patients and Detecting Complications Madhav Swaminathan, MD, FASE Professor of Anesthesiology Division of Cardiothoracic Anesthesia & Critical Care Duke University
More informationMechanical ventricular support is infrequently required for recipients
Cardiopulmonary Support and Physiology Petrofski et al BVS5000 support after cardiac transplantation Jason A. Petrofski, MD a Vijay S. Patel, MD a Stuart D. Russell, MD b Carmelo A. Milano, MD a Objective:
More informationAcute heart failure: ECMO Cardiology & Vascular Medicine 2012
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012 Lucia Jewbali cardiologist-intensivist 14 beds/8 ICU beds Acute coronary syndromes Heart failure/ Cardiogenic shock Post cardiotomy Heart
More informationDEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University
DEMYSTIFYING VADs Nicolle Choquette RN MN Athabasca University Objectives odefine o Heart Failure o VAD o o o o Post Operative Complications Acute Long Term Nursing Interventions What is Heart Failure?
More informationL: Cardiovascular. Saskatchewan Association of Licensed Practical Nurses, Competency Profile for LPNs, 3rd Ed. 107
L: Cardiovascular Saskatchewan Association of Licensed Practical Nurses, Competency Profile for LPNs, 3rd Ed. 107 Major Competency Area: L Cardiovascular Competency: L-1 Cardiovascular Nursing Date: January
More informationPost Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ
Post Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ Art of Good Cooking Good Ingredient Good donor + OK recipient Good technique Good team Good timing Good
More informationPredictors of Low Cardiac Output Syndrome After Isolated Coronary Artery Bypass Surgery: Trends Over 20 Years
Predictors of Low Cardiac Output Syndrome After Isolated Coronary Artery Bypass Surgery: Trends Over 20 Years Khaled D. Algarni, MD, MHS, Manjula Maganti, MS, and Terrence M. Yau, MD, MS Division of Cardiovascular
More informationCardiac disease is well known to be the leading cause
Coronary Artery Bypass Grafting in Who Require Long-Term Dialysis Leena Khaitan, MD, Francis P. Sutter, DO, and Scott M. Goldman, MD Main Line Cardiothoracic Surgeons, Lankenau Hospital, Jefferson Health
More informationManagement of new-onset AF: Initial rate control treatment
Geneva Acute Crdiovascular Care Congress 2014 - October 18-20, 2014 Management of new-onset AF: Initial rate control treatment Antonio Raviele, MD, FESC, FHRS ALFA Alliance to Fight Atrial fibrillation,
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationEmergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationThe first report of the Society of Thoracic Surgeons
REPORT The Society of Thoracic Surgeons National Congenital Heart Surgery Database Report: Analysis of the First Harvest (1994 1997) Constantine Mavroudis, MD, Melanie Gevitz, BA, W. Steves Ring, MD, Charles
More informationThinking outside of the box Perfusion management and myocardial protection strategy for a patient with sickle cell disease
Thinking outside of the box Perfusion management and myocardial protection strategy for a patient with sickle cell disease Shane Buel MS, RRT 1 Nicole Michaud MS CCP PBMT 1 Rashid Ahmad MD 2 1 Vanderbilt
More informationAcid-base management during hypothermic CPB alpha-stat and ph-stat models of blood gas interpretation
Acid-base management during hypothermic CPB alpha-stat and ph-stat models of blood gas interpretation Michael Kremke Department of Anaesthesiology and Intensive Care Aarhus University Hospital, Denmark
More informationTransfusion & Mortality. Philippe Van der Linden MD, PhD
Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:
More informationCardiology. Objectives. Chapter
1:44 M age 1121 Chapter Cardiology Objectives art 1: Cardiovascular natomy and hysiology, ECG Monitoring, and Dysrhythmia nalysis (begins on p. 1127) fter reading art 1 of this chapter, you should be able
More informationMinimally Invasive Aortic Surgery With Emphasis On Technical Aspects, Extracorporeal Circulation Management And Cardioplegic Techniques
Minimally Invasive Aortic Surgery With Emphasis On Technical Aspects, Extracorporeal Circulation Management And Cardioplegic Techniques Konstadinos A Plestis, MD System Chief of Cardiothoracic and Vascular
More informationC1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders
C1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders GENERAL ISSUES REGARDING MEDICAL FITNESS-FOR-DUTY 1. These medical standards apply to Union Pacific Railroad (UPRR) employees
More informationPost-Cardiac Surgery Evaluation
Post-Cardiac Surgery Evaluation 20th Annual Heart Conference October 15, 2016 Gary A Mayman PROFESSOR PEDIATRICS UNIVERSITY OF NEVADA Look Touch Listen Temperature, pulse, respiratory rate, & blood pressure
More informationSurgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
More informationRhondalyn C. McLean. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VII, A. Study Purpose and Rationale
A Randomized Clinical Study To Compare The Intra-Aortic Balloon Pump To A Percutaneous Left Atrial-To-Femoral Arterial Bypass Device For Treatment Of Cardiogenic Shock Following Acute Myocardial Infarction.
More informationTo ECMO Or Not To ECMO Challenges of venous arterial ECMO. Dr Emily Granger St Vincent s Hospital Darlinghurst NSW
To ECMO Or Not To ECMO Challenges of venous arterial ECMO Dr Emily Granger St Vincent s Hospital Darlinghurst NSW The Start: 1972 St Vincent s Hospital The Turning Point ECMO program restarted in 2004
More informationBritish Journal of Anaesthesia 89 (3): 398^04 (2002)
British Journal of Anaesthesia 89 (3): 398^04 (2002) Incidence and risk calculation of inotropic support in patients undergoing cardiac surgery with cardiopulmonary bypass using an automated anaesthesia
More informationEffect of Sodium Nitroprusside during the Payback Period of Cardiopulmonary Bypass on the Incidence of Postoperative Arrhythmias
Effect of Sodium Nitroprusside during the Payback Period of Cardiopulmonary Bypass on the Incidence of Postoperative Arrhythmias Kit V. Arom, M.D., David M. Angaran, M.S., William G. Lindsay, M.D., William
More informationSpecific Basic Standards for Osteopathic Fellowship Training in Cardiology
Specific Basic Standards for Osteopathic Fellowship Training in Cardiology American Osteopathic Association and American College of Osteopathic Internists BOT 07/2006 Rev. BOT 03/2009 Rev. BOT 07/2011
More informationDo Posttransplant Outcomes Differ in Heart Transplant Recipients Bridged With Continuous and Pulsatile Flow Left Ventricular Assist Devices?
Do Posttransplant Outcomes Differ in Heart Transplant Recipients Bridged With Continuous and Pulsatile Flow Left Ventricular Assist Devices? Kimberly N. Hong, MHSA, Alexander Iribarne, MD, MS, Jonathan
More informationValue of serum magnesium estimation in diagnosing myocardial infarction and predicting dysrhythmias after coronary artery bypass grafting
Thorax 1983;38:946-95 Value of serum magnesium estimation in diagnosing myocardial infarction and predicting dysrhythmias after coronary artery bypass grafting RICHARD W BUNTON From the Department of Cardiothoracic
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationBicuspid aortic root spared during ascending aorta surgery: an update of long-term results
Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Nitric Oxide: Might make it Better? J. Hunter Mehaffey, MD, MSc, Robert B. Hawkins, MD, MSc PII: S0022-5223(18)32342-0 DOI: 10.1016/j.jtcvs.2018.08.070 Reference: YMTC 13398 To appear
More informationCrisis Management During Liver Transplant Surgery Liver and Intensive Care Group of Europe Newcastle upon Tyne 2005
Crisis Management During Liver Transplant Surgery Liver and Intensive Care Group of Europe Newcastle upon Tyne 2005 M. Susan Mandell M.D. Ph. D. Department of Anesthesiology University of Colorado Health
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute coronary syndrome(s), anticoagulant therapy in, 706, 707 antiplatelet therapy in, 702 ß-blockers in, 703 cardiac biomarkers in,
More informationIntraoperative Myocardial Protection: Current Trends and Future Perspectives
Intraoperative Myocardial Protection: Current Trends and Future Perspectives Gideon Cohen, MD, Michael A. Borger, MD, Richard D. Weisel, MD, and Vivek Rao, MD, PhD Division of Cardiovascular Surgery, The
More informationThe operative mortality rate after redo valvular operations
Clinical Outcomes of Redo Valvular Operations: A 20-Year Experience Naoto Fukunaga, MD, Yukikatsu Okada, MD, Yasunobu Konishi, MD, Takashi Murashita, MD, Mitsuru Yuzaki, MD, Yu Shomura, MD, Hiroshi Fujiwara,
More informationThe strategy of sequential use of antegrade and. Can Retrograde Cardioplegia Alone Provide Adequate Protection for Cardiac Valve Surgery?
Can Retrograde Cardioplegia Alone Provide Adequate Protection for Cardiac Valve Surgery?* Nirupama G. Talwalkar, MD, FCCP; Gerald M. Lawrie, MD, FCCP; Nan Earle, BS; and Michael E. DeBakey, MD, FCCP Background:
More informationManagement of a Patient after the Bidirectional Glenn
Management of a Patient after the Bidirectional Glenn Melissa B. Jones MSN, APRN, CPNP-AC CICU Nurse Practitioner Children s National Health System Washington, DC No Disclosures Objectives qbriefly describe
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationMyocardial Protection Principles. David J Chambers
David J Chambers Cardiac Surgical Research/Cardiothoracic Surgery The Rayne Institute (King s College London) Guy s & St Thomas NHS Foundation Trust St Thomas Hospital London UK ScanSect, Aarhus, Denmark.
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationIn the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension
In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial
More informationMWLCEMS SYSTEM Continuing Education Packet Management of the Acute MI Patient
MWLCEMS SYSTEM Continuing Education Packet Management of the Acute MI Patient In this CE we will discuss the patient presenting with an acute ST-Elevation Myocardial Infarction (STEMI) Definition: Myocardial
More informationA Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery
A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery Arman Kilic, MD 1, Rika Ohkuma, MD 1, J. Trent Magruder, MD 1, Joshua C. Grimm, MD 1, Marc Sussman, MD 1, Eric B. Schneider, PhD 1,
More informationIntroduction. Study Design. Background. Operative Procedure-I
Risk Factors for Mortality After the Norwood Procedure Using Right Ventricle to Pulmonary Artery Shunt Ann Thorac Surg 2009;87:178 86 86 Addressor: R1 胡祐寧 2009/3/4 AM7:30 SICU 討論室 Introduction Hypoplastic
More informationConventional CABG Or On Pump Beating Heart: A Difference In Myocardial Injury?
Conventional CABG Or On Pump Beating Heart: A Difference In Myocardial Injury? Kornelis J. Koopmans Medical Center Leeuwarden Leeuwarden, The Netherlands I have no disclosures Disclosures Different techniques
More informationManagement of Acute Shock and Right Ventricular Failure
Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering, Cleveland Clinic NONE Disclosures CARDIOGENIC SHOCK
More informationCounterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece
John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87
More informationNothing to Disclose. Severe Pulmonary Hypertension
Severe Ronald Pearl, MD, PhD Professor and Chair Department of Anesthesiology Stanford University Rpearl@stanford.edu Nothing to Disclose 65 year old female Elective knee surgery NYHA Class 3 Aortic stenosis
More informationThe prevalence of permanent cardiac pacing after. Permanent Cardiac Pacing After a Cardiac Operation: Predicting the Use of Permanent Pacemakers
Permanent Cardiac Pacing After a Cardiac Operation: Predicting the Use of Permanent Pacemakers Richard S. Gordon, BSc, Joan Ivanov, MSc, Gideon Cohen, MD, and Anthony L. Ralph-Edwards, MD Division of Cardiovascular
More informationSurgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011
Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite
More informationThe Effect of Acute Coronary Artery Occlusion during Cardioplegic Arrest
The Effect of Acute Coronary Artery Occlusion during Cardioplegic Arrest and Reperfusion on Myocardial Preservation John H. Rousou, M.D., Richard M. Engelman, M.D., William A. Dobbs, Ph.D., and Mooideen
More informationUseful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication vs Benefit? Mortality? Morbidity?
Preoperative intraaortic balloon counterpulsation in high-risk CABG Stefan Klotz, M.D. Preoperative IABP in high-risk CABG Questions?? Useful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication
More informationHemodynamic Monitoring and Circulatory Assist Devices
Hemodynamic Monitoring and Circulatory Assist Devices Speaker: Jana Ogden Learning Unit 2: Hemodynamic Monitoring and Circulatory Assist Devices Hemodynamic monitoring refers to the measurement of pressure,
More informationMiECC AND THE BRAIN Helena Argiriadou
MiECC AND THE BRAIN Helena Argiriadou Ass. Professor of Anesthesiology Aristotle University of Thessaloniki, Cardiothoracic Department AHEPA University Hospital Thessaloniki, Greece NEUROLOGIC INJURY AND
More information